Â鶹ӳ»­

Hojong Yoon, Ph.D. 
Principal Investigator
Assistant Professor, Experimental Therapeutics
Assistant Member, James P. Allison Institute

Hojong received his Ph.D. in chemical biology from Harvard University in 2021, where he worked on elucidating the mechanism behind molecular glue-induced target protein degradation. He completed his postdoctoral training in the laboratory of Dr. Benjamin Ebert at the Broad Institute of MIT and Harvard, where he  developed a chemoproteomic approach to identify molecular glues and also gained proficiency in a fluorescent reporter-based CRISPR screen to identify key mediators of targeted protein degradation.

In 2025, he started his independent laboratory at MD Anderson Cancer Center. Hojong has published in many high-profile journals as the first author, including Nature, Nature Chemical Biology, Journal of Medicinal Chemistry. His research focuses on understanding drug mechanisms at the molecular level and developing new drug modalities towards undruggable targets.